You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
McKinsey
AstraZeneca
Merck
Baxter

Last Updated: April 14, 2021

DrugPatentWatch Database Preview

VELETRI Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Veletri patents expire, and what generic alternatives are available?

Veletri is a drug marketed by Actelion Pharms Ltd and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has nineteen patent family members in fifteen countries.

The generic ingredient in VELETRI is epoprostenol sodium. There are seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the epoprostenol sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Veletri

A generic version of VELETRI was approved as epoprostenol sodium by TEVA PHARMS USA on April 23rd, 2008.

  Start Trial

Drug patent expirations by year for VELETRI
Drug Prices for VELETRI

See drug prices for VELETRI

Recent Clinical Trials for VELETRI

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Duke UniversityPhase 4

See all VELETRI clinical trials

Pharmacology for VELETRI
Drug ClassProstacycline Vasodilator
Physiological EffectVasodilation
Paragraph IV (Patent) Challenges for VELETRI
Tradename Dosage Ingredient NDA Submissiondate
VELETRI INJECTABLE;INJECTION epoprostenol sodium 022260 2017-03-31

US Patents and Regulatory Information for VELETRI

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actelion Pharms Ltd VELETRI epoprostenol sodium INJECTABLE;INJECTION 022260-002 Jun 28, 2012 RX Yes No   Start Trial   Start Trial   Start Trial
Actelion Pharms Ltd VELETRI epoprostenol sodium INJECTABLE;INJECTION 022260-001 Jun 27, 2008 RX Yes Yes   Start Trial   Start Trial   Start Trial
Actelion Pharms Ltd VELETRI epoprostenol sodium INJECTABLE;INJECTION 022260-002 Jun 28, 2012 RX Yes No   Start Trial   Start Trial Y   Start Trial
Actelion Pharms Ltd VELETRI epoprostenol sodium INJECTABLE;INJECTION 022260-001 Jun 27, 2008 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Medtronic
Johnson and Johnson
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.